Prospectus for listing of Idorsia published

10 June 2017

Swiss biotech firm Actelion (SIX: ATLN) has published the listing prospectus relating to the listing of Idorsia shares on the SIX Swiss Exchange.

As part of the previously announced agreement for the $30 billion acquisition of Actelion by US healthcare giant Johnson & Johnson (NYSE: JNJ), the Swiss company’s drug discovery and early-stage development assets will be spun out into the new Idorsia.

It is expected that the settlement of the tender offer by J&J will take place on June 16. The demerger distribution, approved by the General Meeting of Actelion shareholders held on April 5, 2017, will take place concurrently, whereby all Actelion shareholders (whether they tendered their shares or not) will receive one Idorsia share per each Actelion share held on June 13, 2017. It is expected that Idorsia shares will be listed and commence trading on SIX Swiss Exchange on June 16, 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK